Metropolis Healthcare Earnings Call Transcript: Key Takeaways
Metropolis Healthcare reports a strong Q1FY27, beating its own revenue guidance through volume-led growth and aggressive tier-2/3 expansion.
- Call
- Guides 15% growth
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Metropolis Healthcare reports a strong Q1FY27, beating its own revenue guidance through volume-led growth and aggressive tier-2/3 expansion.
Metropolis Healthcare reports strong Q1FY27 results with Revenue at INR 450 Cr (up 17% YoY) and EBITDA at INR 113 Cr (up 27% YoY).
Metropolis Healthcare reports strong FY26 performance with 23.6% YoY revenue growth and 24.4% EBITDA margin. Strategy focuses on network productivity, genomics, and expanding 'mini hubs' for pathology and basic radiology.
Metropolis Healthcare shows strong organic momentum, beating FY26 revenue guidance. Management is shifting focus from aggressive lab expansion to productivity-led growth and margin recovery through operating leverage.
Metropolis Healthcare reports strong FY26 growth, with Group Revenue up 24% and PAT up 31% YoY. The company is executing its 'Metropolis 3.0' strategy focused on specialty tests and network expansion.